Steven Holtzman先生于2016年加入Decibel Therapeutics，担任总裁兼首席执行官。Decibel发现并研发了新的治疗方法来治疗失聪和其他听力障碍。在Decibel之前，他曾担任Biogen企业发展执行副总裁。在Biogen, 他创建并领导项目团队和管理团队通过了八项新药批准。此外，他还领导商业开发和企业并购团队，成功完成大量交易。在Biogen之前，他曾担任癌症药物研发公司Infinity Pharmaceuticals的创始人、首席执行官和董事会主席。此外他还是Millennium Pharmaceuticals (现为Takeda Oncology)的早期领导者和首席商务官，该公司是大规模遗传学和基因组学的先驱。他也是第一家转基因动物公司DNX公司的创始人、董事会成员和执行副总裁。他还是Visterra、Warp Drive和Molecular Partners的董事会成员。同时他也是Humatics, Compugen, 以及Marauder Therapeutics的战略商业顾问。在非营利领域，Steven目前是Berklee音乐学院的董事，此前他曾担任Hastings伦理和生命科学中心董事会副主席。1996年到2001年间，他被总统任命为美国国家生物伦理咨询委员会成员。史蒂夫拥有密歇根州立大学哲学学士学位以及牛津大学Corpus Christi学院哲学硕士学位。
Steven Holtzman joined Decibel Therapeutics as president chief and executive officer in 2016. Decibel discovers and develops novel therapeutic approaches to treat hearing loss and other hearing disorders. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc. At Biogen, Steve created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in largescale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Warp Drive Bio, and Molecular Partners. He serves as a strategic business advisor to Humatics, Compugen, and Marauder Therapeutics. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission. Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.
杨璐菡 博士 Luhan Yang Ph.D.
董事、首席执行官 Director & CEO
2018年被《纽约时报》评选为“当代高瞻远瞩的30位人物”。 2017年被《彭博商业周刊》评选为“全球最有影响50位人物”； 2017年当选达沃斯世界经济论坛“全球青年领袖”；2014年杨博士获选《福布斯》 “全球30位30岁以下科学和医疗领域领军人物”， 并荣获“青年企业家项目”（Young Entrepreneur Initiative）竞赛的桂冠；
Dr. Luhan Yang is Chief Executive Officer of Qihanbio, co-founder and Chief Scientific Officer of eGenesis. Dr. Yang is currently leading the two companies to make unremitting efforts for research and development of xenotransplantation. She was selected by the New York Times as "30 people with far-sighted vision in the contemporary era"(2018). And honored in the Bloomberg 50 (2017), named “Young Global Leader” by the World Economic Forum (2017), was among “30 Under 30” in Science and Healthcare by Forbes Magazine (2014) and was a laureate of the “Young Entrepreneur Initiative” competition (2014).
Dr. Yang holds B.S. degrees in Biology and Psychology from Peking University and a Ph.D. in Human Biology and Translational Medicine from Harvard Medical School.
沈南鹏 Neil Shen
沈南鹏先生担任红杉资本全球执行合伙人，红杉资本中国基金创始及执行合伙人 ，携程旅行网和如家连锁酒店创始人。他还担任第十三届全国政协委员、现任耶鲁中国中心理事会主席 、中国企业家论坛理事 、中国证券投资基金业协会创业投资基金专业委员会副主席,亚洲协会理事、上海交通大学校董等多项职务。
沈南鹏先生位列美国《福布斯》杂志2018年，2019年“全球最佳创投人”榜首 。所获奖项主要包括：《福布斯》2012-2018年度“全球最佳投资人”榜单中排名最高的华人投资者 、《财富》2015-2017年度“中国最具影响力的50位商界领袖”和 “中国最具影响力的30位投资人”、CB Insights -《纽约时报》2017年度“全球20位顶尖风险投资人” 、《福布斯》百年百位全球最伟大商业思想家等多项大奖 。
Neil Shen is the Founding & Managing Partner of Sequoia Capital China. He is also a co-founder of Ctrip.com (NASDAQ: CTRP) and Home Inns (NASDAQ: HMIN).
Mr. Shen also serves as a member of the 13th CPPCC National Committee, the Board Chairman of Yale Leadership Center in China, Director of China Entrepreneur Forum (CEF), Vice Chairman of VC Funds Committee of Asset Management Association of China, Trustee of Asia Society, and a Trustee of Shanghai Jiao Tong University.
Mr. Shen topped Forbes magazine's "Best Venture Capital Player in the World" in 2018 and 2019. He was the highest- ranked Chinese investor in Forbes' "World's Best Investor" list from 2012 to 2018. Mr. Shen was selected as Fortune's "China's 50 Most Influential Business Leaders" and "China's 30 Most Influential Investors", named "World's 20 Top Venture Investors" by CB Insights-"New York Times" in 2015-2017 2017, and was among the world's 100 greatest business thinkers by Forbes Magazine.
Mr. Shen received his Master’s degree from the School of Management at Yale University and his Bachelor’s degree from Shanghai Jiao Tong University.
夏汲清 博士 Jake Xia Ph.D.
Jake Xia is a Managing Director at Harvard Management Company (HMC). He and the team together make investments for Harvard University’s endowment in all asset classes, strategies and regions. He joined HMC in June 2013 as the Chief Risk Officer focusing on asset allocation and portfolio management.
Prior to joining HMC, Mr. Xia spent 17 years at Morgan Stanley, serving as head of global fixed income trading risk and head of global interest rates derivative trading in New York, managing trading groups across the globe. Previously, Mr. Xia was Morgan Stanley’s co-head of fixed income in Japan. Prior to Morgan Stanley, Mr. Xia served as vice president of fixed income research at Salomon Brothers in New York and was a research scientist at Schlumberger-Doll Research.
Mr. Xia holds a PhD in electrical engineering and computer science from Massachusetts Institute of Technology.
Bob More先生是Alta Partners公司的董事总经理。此前，他是比尔和梅林达盖茨基金会的高级顾问，并领导了“全球健康风险倡议”。在此之前，他是Frazier Healthcare Ventures和Domain Associates的普通合伙人。
More先生是Kauffman Fellows Program的创始董事会成员，并在“One Revolution”和“Foundation for Innovative New Diagnostics (FIND)”董事会任职。More先生拥有米德尔伯里学院学士学位，以及弗吉尼亚大学达顿商学院硕士学位。
Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” Prior to that, he was a General Partner with Frazier Healthcare Ventures and Domain Associates.
Mr. More was a founding board member of the Kauffman Fellows Program and serves on the boards of One Revolution and the Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.